Xenetic Biosciences Stock (NASDAQ:XBIO)
Previous Close
$4.10
52W Range
$2.78 - $5.20
50D Avg
$3.98
200D Avg
$4.00
Market Cap
$6.62M
Avg Vol (3M)
$24.98K
Beta
2.26
Div Yield
-
XBIO Company Profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
XBIO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| REVB | Revelation Biosciences, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| GOVX | GeoVax Labs, Inc. |
| VRAX | Virax Biolabs Group Limited |
| TNXP | Tonix Pharmaceuticals Holding Corp. |
| IMMX | Immix Biopharma, Inc. |
| CYTO | Altamira Therapeutics Ltd. |
| DRUG | Bright Minds Biosciences Inc. |
| ZURA | Zura Bio Limited |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |
| ENVB | Enveric Biosciences, Inc. |
| PALI | Palisade Bio, Inc. |
| ATNF | 180 Life Sciences Corp. |